vs

Side-by-side financial comparison of RENASANT CORP (RNST) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

RENASANT CORP is the larger business by last-quarter revenue ($273.8M vs $151.7M, roughly 1.8× Tarsus Pharmaceuticals, Inc.). RENASANT CORP runs the higher net margin — 32.2% vs -5.5%, a 37.7% gap on every dollar of revenue. Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 29.3%).

Renasant Bank is an American regional commercial financial institution based in Tupelo, Mississippi. The bank has more than 280 branches in Alabama, Florida, Georgia, Mississippi, Louisiana, Tennessee, North Carolina and South Carolina. Renasant Bank operates under the parent company Renasant Corporation and is affiliated with Renasant Nation, a platform through which they publish blogs and shows.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

RNST vs TARS — Head-to-Head

Bigger by revenue
RNST
RNST
1.8× larger
RNST
$273.8M
$151.7M
TARS
Higher net margin
RNST
RNST
37.7% more per $
RNST
32.2%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
29.3%
RNST

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
RNST
RNST
TARS
TARS
Revenue
$273.8M
$151.7M
Net Profit
$88.2M
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
32.2%
-5.5%
Revenue YoY
128.4%
Net Profit YoY
112.5%
63.8%
EPS (diluted)
$0.94
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNST
RNST
TARS
TARS
Q1 26
$273.8M
Q4 25
$278.4M
$151.7M
Q3 25
$269.5M
$118.7M
Q2 25
$267.2M
$102.7M
Q1 25
$170.7M
$78.3M
Q4 24
$167.1M
$66.4M
Q3 24
$220.3M
$48.1M
Q2 24
$163.8M
$40.8M
Net Profit
RNST
RNST
TARS
TARS
Q1 26
$88.2M
Q4 25
$78.9M
$-8.4M
Q3 25
$59.8M
$-12.6M
Q2 25
$1.0M
$-20.3M
Q1 25
$41.5M
$-25.1M
Q4 24
$44.7M
$-23.1M
Q3 24
$72.5M
$-23.4M
Q2 24
$38.8M
$-33.3M
Operating Margin
RNST
RNST
TARS
TARS
Q1 26
Q4 25
34.8%
-5.3%
Q3 25
27.9%
-12.2%
Q2 25
1.0%
-21.6%
Q1 25
30.4%
-33.5%
Q4 24
29.8%
-36.8%
Q3 24
44.2%
-52.3%
Q2 24
29.6%
-81.6%
Net Margin
RNST
RNST
TARS
TARS
Q1 26
32.2%
Q4 25
28.4%
-5.5%
Q3 25
22.2%
-10.6%
Q2 25
0.4%
-19.8%
Q1 25
24.3%
-32.1%
Q4 24
26.8%
-34.8%
Q3 24
32.9%
-48.7%
Q2 24
23.7%
-81.6%
EPS (diluted)
RNST
RNST
TARS
TARS
Q1 26
$0.94
Q4 25
$0.78
$-0.17
Q3 25
$0.63
$-0.30
Q2 25
$0.01
$-0.48
Q1 25
$0.65
$-0.64
Q4 24
$0.70
$-0.57
Q3 24
$1.18
$-0.61
Q2 24
$0.69
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNST
RNST
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$1.2B
$417.3M
Total DebtLower is stronger
$806.2M
$72.4M
Stockholders' EquityBook value
$3.9B
$343.4M
Total Assets
$27.1B
$562.2M
Debt / EquityLower = less leverage
0.21×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNST
RNST
TARS
TARS
Q1 26
$1.2B
Q4 25
$1.1B
$417.3M
Q3 25
$1.1B
$401.8M
Q2 25
$1.4B
$381.1M
Q1 25
$1.1B
$407.9M
Q4 24
$1.1B
$291.4M
Q3 24
$1.3B
$317.0M
Q2 24
$851.9M
$323.6M
Total Debt
RNST
RNST
TARS
TARS
Q1 26
$806.2M
Q4 25
$499.8M
$72.4M
Q3 25
$558.9M
$72.3M
Q2 25
$557.0M
$72.1M
Q1 25
$433.3M
$72.0M
Q4 24
$430.6M
$71.8M
Q3 24
$433.2M
$71.7M
Q2 24
$428.7M
$71.6M
Stockholders' Equity
RNST
RNST
TARS
TARS
Q1 26
$3.9B
Q4 25
$3.9B
$343.4M
Q3 25
$3.8B
$335.1M
Q2 25
$3.8B
$332.6M
Q1 25
$2.7B
$342.5M
Q4 24
$2.7B
$224.5M
Q3 24
$2.7B
$237.5M
Q2 24
$2.4B
$252.2M
Total Assets
RNST
RNST
TARS
TARS
Q1 26
$27.1B
Q4 25
$26.8B
$562.2M
Q3 25
$26.7B
$534.6M
Q2 25
$26.6B
$495.0M
Q1 25
$18.3B
$500.8M
Q4 24
$18.0B
$377.0M
Q3 24
$18.0B
$376.3M
Q2 24
$17.5B
$376.8M
Debt / Equity
RNST
RNST
TARS
TARS
Q1 26
0.21×
Q4 25
0.13×
0.21×
Q3 25
0.15×
0.22×
Q2 25
0.15×
0.22×
Q1 25
0.16×
0.21×
Q4 24
0.16×
0.32×
Q3 24
0.16×
0.30×
Q2 24
0.18×
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNST
RNST
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNST
RNST
TARS
TARS
Q1 26
Q4 25
$271.5M
$19.3M
Q3 25
$135.5M
$18.3M
Q2 25
$-77.3M
$-29.4M
Q1 25
$106.2M
$-20.7M
Q4 24
$106.4M
$-22.2M
Q3 24
$-1.7M
$-8.7M
Q2 24
$-49.1M
$-14.4M
Free Cash Flow
RNST
RNST
TARS
TARS
Q1 26
Q4 25
$237.8M
$13.0M
Q3 25
$120.1M
$16.3M
Q2 25
$-87.5M
$-30.4M
Q1 25
$101.3M
$-21.2M
Q4 24
$92.8M
$-22.3M
Q3 24
$-5.3M
$-8.9M
Q2 24
$-52.6M
$-15.4M
FCF Margin
RNST
RNST
TARS
TARS
Q1 26
Q4 25
85.4%
8.6%
Q3 25
44.6%
13.8%
Q2 25
-32.7%
-29.6%
Q1 25
59.4%
-27.1%
Q4 24
55.5%
-33.5%
Q3 24
-2.4%
-18.6%
Q2 24
-32.1%
-37.8%
Capex Intensity
RNST
RNST
TARS
TARS
Q1 26
Q4 25
12.1%
4.2%
Q3 25
5.7%
1.6%
Q2 25
3.8%
1.0%
Q1 25
2.8%
0.8%
Q4 24
8.2%
0.1%
Q3 24
1.6%
0.6%
Q2 24
2.1%
2.5%
Cash Conversion
RNST
RNST
TARS
TARS
Q1 26
Q4 25
3.44×
Q3 25
2.27×
Q2 25
-75.92×
Q1 25
2.56×
Q4 24
2.38×
Q3 24
-0.02×
Q2 24
-1.26×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RNST
RNST

Net Interest Income$223.6M82%
Noninterest Income$50.3M18%

TARS
TARS

Segment breakdown not available.

Related Comparisons